Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: Data on NORMACODEM project;Valor diagnóstics y correlaciones funcionales de la escala ADAS-Cog en la enfermedad de Alzheimer: Datos del proyecto NORMACODEM

Neurologia

Volumn 22, Issue 8, 2007, Pages 493-501

  Monllau, A ^a   Peña Casanova, Jordi ^a,b   Blesa, R ^c   Aguilar, M ^d   Bohm P ^a,b,e   Sol, J M ^f   Hernandez G ^f   Manero, R M ^b   Espel, G ^b   Marti A M ^b   Meza, M ^b   Soler, T ^g   Zabay, C ^g   Riera, M ^g   Castellvi, M ^g   Rivero, A I ^g   Santiago, M J ^g   Toiran, E ^g   Crespo, M C ^d  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e I3 Research   (Spain)

^f PFIZER INC   (United States)

^g Hospital del Mar ^*  (Spain)

Author keywords

ADAS COG scale; Alzheimer's disease; Total ADAS scale

Indexed keywords

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMENTIA; DIAGNOSTIC VALUE; EDUCATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RATING SCALE; ROC CURVE; SCORING SYSTEM; AGE; AGED; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; EDUCATIONAL STATUS; HOSPITALIZATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ACTIVITIES OF DAILY LIVING; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; DEMENTIA; EDUCATIONAL STATUS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 36148969317     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. a ed. Washington: American Psychiatrie Press, 1994.
2. Organización Mundial de Ia Salud. CIE-10. Trastornos mentales y de comportamíento. Pautas de dîagnóstico y de actuación en atención primaria. Madrid: Meditor, 1992.
3. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
4. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, et al. Screening for dementia with the Memory Impairment Screen. Neurology 1999;52:231-8.
5. Solomon PR, Hirschoff A, Kelly B. A 7-minute neurocognitive screening battery highly sensitive to Alzheimer's disease. Arch Neurol 1998;55:349-55.
6. Roth M, Hupper F, Tym E, Mountjoy C. CAMDEX: the Cambridge index for mental disorder for the elderly. Cambridge: Cambridge University Press, 1988.
7. Mohs RC, Rosen WG, Davis KL. The Alzheimer's Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychofarmacol Bull 1983;19:448-50.
8. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer disease. Am J Psychiatry 1984;141:1356-64.
9. Mohs R, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessments Scale that broaden its scope. The Alzheimer Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:13-21.
10. Peña-Casanova J, Guardia J, Bertrán Serra I, Jarne A. Versión abreviada del Test Barcelona (I): subtests y perfiles normales. Neurología 1997;12:19-23.
11. Guardia J, Peña Casanova J, Bertrán-Serra I, Manero R, Meza M, Böhm P. Versión abreviada del Test Barcelona (II): puntuación global normalizada, Neurología 1997;12:112-7.
12. Peña-Casanova J, Meza M, Bertran Serra I, Manero R, Espel A, Marti A, et al. Versión abreviada del Test Barcelona (III): validez de criterio con la ADAS-Cog. Neurología 1997;12:117-9.
13. Peña-Casanova J. Programa integrado en la exploración neuropsicológica. Test Barcelona. Manual. Barcelona: Masson, 1990.
14. Peña-Casanova J. Programa integrado en la exploración neuropsicológica. Test Barcelona. Bases teóricas, objetivos y contenidos. Rev Logop Fon Audiol 1991;112:66-79.
15. Gramunt N, Cejudo JC, Serra A, Guardia J, Peña-Casanova J. Capacidades abstractas: normas ampliadas del Test Barcelona. Neurologia 1998;13:277-86.
16. Peña-Casanova J, Aguilar M, Bertrán-Serra I, Santacruz P, Hernández G, Insa R, et al. Normalización de instrumentos cognitivos y funcionales para la evaluación de la demencia. (NORMACODEM): objetivos, contenidos y población. Neurología 1997;11:61-7.
17. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertrán-Serra I, Hernández G, et al. Clinical validity of de mini-mental state for Spanish speaking communities. Neuropsychologia 2001;39:1150-7.
18. Peña-Casanova J, Aguilar M, Santacruz P, Bertran-Serra I, Hernández G, Sol JM, et al. Adaptación y normalization españolas de la Alzheimer's Disease Assessment Scale (NORMACODEM) (y II). Neurología 1997;12:69-77.
19. Böhm P, Peña-Casanova J, Aguilar M, Hernández G, Sol JM, Blesa R. Clinical validity and utility of the interview for deterioration of daily living in dementia for Spanish-speaking communities. International Psychogeriatrics 1998;10:261-70.
20. Soler T, Pujol M, Peña-Casanova J, Hernández G, Sol JM, Aguilar M. Adaptation and standardization of the Geriatric Evaluation of Relative's Rating Instrument (GERRI), for Spain. Neurología 2002;17:193-9.
21. Peña-Casanova J, Monllau A, Böhm P, Blesa R, Aguilar M, Sol JM, et al. Correlación cognitivo-funcional en la de demencia tipo Alzheimer: a propósito del Test Barcelona Abreviado. Neurologia 2005;20:4-8.
22. Peña-Casanova J, Monllau A, Böhm P, Aguilar M, Sol JM, Hernández G, et al. Valor diagnóstico y fiabilidad test-retest de la escala de demencia de Blessed (BDRS) para la enfermedad de Alzheimer: datos del proyecto NORMACODEM. Neurologia 2005;20:349-55.
23. Monllau A, Aguilar M, Peña-Casanova J, Blesa R, Sol JM, Hernández G, y grupo NORMACODEM. Adaptación de la escala de Evaluación Rápida de la Discapacidad-2 (The Rapid Disability Rating Scale-2) para la enfermedad de Alzheimer: datos del proyecto NORMACODEM. Neurología 2006;20:282-8.
24. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974;2:201-7.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
26. Hughes CP, Berg L, Danzinger WL. A new clinical scale for the staging of dementia. Br J Psychiatr 1988;140:566-72.
27. Zee RF, Landreth ES, Vicari SK, Feldman E, Belman J, Andrise A, et al. Alzheimer Disease Assessment Scale: useful for both early detection and staging of dementia of Alzheimer type. Alzheimer Dis Assoc Disord 1992;6:89-102.
28. Schwarb S, Koberle S, Spiegel R. The Alzheimer's Disease Assessment Scale (ADAS): an instruntment for early diagnosis of dementia? Int J Geriatr Psychiatry 1988;3:45-53.
29. Linn MW. A Rapid Disability Rating Scale. J Am Ger Soc 1967;12:211-4.
30. Linn MW, Linn BS. The Rapid Disability Rating Scale-Part 2. J Am Ger Soc 1982;139:1136-9.
31. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-11.
32. Teunisse S, Derix MM, Crevel H. Assessing the severity of dementia. Patient and caregiver. Arch Neurol 1991;48:274-7.
33. Weyer G, Ihl R, Schambach M. Alzheimer's Disease Assessment Scale (ADAS). Deutschsprachige Bearbeitung. Dokumentationsbogen und Testmaterial. Weinheim: Beltz, 1992.
34. Fioravanti M, Nacca D, Buckley AE, Ferrario E, Varetto O, Mogni P, et al. The Italian version of the Alzheimer's Disease Assessment Scale (ADAS): psychometric and normative characteristics from a normal aged population. Arch Gerontol Geriatr 1994;19:21-30.
35. Puel M, Hugonot-Diener L. Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia. Presse Med 1996;25:1028-32.
36. Tsolaki M, Fountoulakis K, Nakopoulou E, Kazis A, Mohs RC. Alzheimer's Disease Assessment Scale: the validation of the scale in Greece in elderly demented patients and normal subjects. Dement Geriatr Cogn Disord 1997;8:273-80.
37. Kolibas E, Korinkova V, Novotny V, Vajdickova K, Hunakova D. ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)-validation of the Slovak version. Bratisl Lek Listy 2000;10:598-602.
38. Schultz R, Siviero M, Bertolucci P. The cognitive subscale of the «Alzheimer's Disease Assessment Scale» in a Brazilian sample. Braz J Med Biol Res 2001;34:1295-302.
39. Hannesdottir K, Snaedal J. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in a Icelandic elderly population. Nord J Psychiatry 2002;56:201-6.
40. Youn JC, Lee DY, Kim KW, Lee JH, Jhoo JH, Lee KU, et al. Development of the Korean version of Alzheimer's Disease Assessment Scale (ADAS-K). Int J Geriatr Psychiatry 2002;17:797-803.
41. Manzano JM, Llorca G, Ledesma A, Lopez JJ. Adaptación española de la Alzheimer's Disease Assessment Scale (ADAS). Actas Luso-Esp Neurol Psiquiatr 1994;22:64-70.
42. Pascual LF, Saz P, Larumbe R, Martínez-Lage P, Muruzabal J, Morales F, et al. Estandarización de una población española de la escala ADAS. (Alzheimer's Disease Assessment Scale). Neurologia 1997;12:238-44.
43. Verhey FR, Houx P, Van Lang N, Huppert F, Stoppe G, Saerens J, et al. Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID). Int J Geriatr Psychiatry 2004;19:41-50.
44. Caro J, Ward A, Ishak K, Migliaccio-Walle K, Getsios D, Papadopoulos G, et al. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? BMC Neurol 2002;2:6.
45. Graham D, Cully J, Snow A, Massman, P, Doody R. The Alzheimer's Disease Assessment. Normative Data for Older Adult Controls. Alzheimer Dis Assoc Disord. 2004;18:236-40.
46. Kramer-Ginzberg E, Mohs RC, Aryan M, Lobel D, Silverman JM, Davidson M, et al. Predictors of course for Alzheimer patients in a longitudinal study. Psychofarmacol Bulletin 1988;24:458-62.
47. Stern RG, Mohs RC, Davidson KL, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-6.
48. Liu HC, Teng EL, Cuing YY, Lin KN, Fun JL, Wang PN. The Alzheimer's Disease Assessment Scale: findings from a low-education population. Dement Geriatr Cogn Disord 2002;13:21-6.
49. Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15:174-83.
50. F-D-C. Reports, Inc. FDA guidance on Alzheimer's drugs clinical utility assessments. FDA. Reports (The pink Sheet't) 1992;54:13-5.
51. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.
52. Zemlan FP, Keys M, Richter RW, Strub RL. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. Life Sciences 1996;58:1823-32.
53. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004;20:1747-52.
54. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283.
55. Orgogozo JM, Rigaud AS, Stoffler, Mobius HJ, Forette FA. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-9.
56. Pomara N, Peskind ER, Potkin SG, McDonald S, Xie Y, Gergel L. Memantine monoterapy is efective and safe for treatment of mild to moderate Alzheimer's disease: a randomised controlled trial. Neurobiol Aging 2004;25:19.
57. Bars PL, Katz N, Berman MM. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-32.
58. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.
59. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4.
60. Bullock R. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 2002;180:135-9.
61. Schneider L. Inhibidores de la colinesterasa: presente y futuro. En: Martínez JM, Khachaturian Z. Alzheimer XXI: ciencia y sociedad. Barcelona: Masson, 2001; p. 245-62.
62. Mohr E, Lynn B, Anderson R, Constant J. Diseño de ensayos clĩnicos en la época de los tratamientos con demncia: dificultades y opciones. En: Gautier S, Scheltens P, Cummings J, editores. Enfermedad de Alzheimer y trastornos relacionados. Barcelona: Ars Medica, 2006; p. 113-43.
63. Peña-Casanova J. Alzheimer's disease Assessment Scale-Cognitive in Clinical Pratice. Int Psychogeriatr 1997;9(Suppl. 1):105-14.